These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3713199)

  • 1. Dose related sequence of effects induced by the DA agonist 2-(N,N-dipropyl)-amino-5,6-dihydroxytetralin.
    Doaré L; Puech AJ; Simon P
    J Pharmacol; 1986; 17(1):60-4. PubMed ID: 3713199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
    Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
    Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
    Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH
    J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of dihydroxy-2-aminotetraline (DATs) on dopamine and beta type adenylate cyclases.
    Sheppard H; Burghardt CR; Long JP
    Res Commun Chem Pathol Pharmacol; 1978 Feb; 19(2):213-24. PubMed ID: 205926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist.
    Pawłowski L; Siwanowicz J; Bigajska K; Przegaliński E
    Pol J Pharmacol Pharm; 1985; 37(2):179-96. PubMed ID: 4048012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent response of central dopaminergic systems to buspirone in mice.
    Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Gursale SC; Balsara JJ
    Indian J Exp Biol; 2008 Oct; 46(10):704-14. PubMed ID: 19024168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo dopamine receptor agonist binding in rat brain: relation with pharmacological effects.
    Feenstra MG; Rollema H; Mulder TB; De Vries JB; Horn AS
    Eur J Pharmacol; 1983 Jun; 90(4):433-6. PubMed ID: 6684056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential activation by some 2-aminotetralin derivatives of the receptor mechanisms in the nucleus accumbens of rats which mediate hyperactivity and stereotyped biting.
    Costall B; Naylor RJ; Cannon JG; Lee T
    Eur J Pharmacol; 1977 Feb; 41(3):307-19. PubMed ID: 556988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-methyl,N-propargyl-2-aminotetralins:novel dopamine agonists with monoamine oxidase inhibiting properties.
    Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Horn AS
    Eur J Pharmacol; 1985 Feb; 109(2):229-40. PubMed ID: 3922776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of both dopaminergic and alpha-adrenergic receptors in the hypomotility induced by dibenzoyl-6,7-ADTN.
    Sumners C; De Vries JB; Dijkstra D; Horn AS
    Eur J Pharmacol; 1981 Apr; 70(4):541-50. PubMed ID: 6113149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topographical analysis of the actions of 2(N,N-dipropyl)amino-5,6-dihydroxytetralin to cause biting behaviour and locomotor hyperactivity from the striatum of the guinea-pig.
    Costall B; De Souza CX; Naylor RJ
    Neuropharmacology; 1980 Jul; 19(7):623-31. PubMed ID: 7190654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.